Jul 25, 2024, 20:13
Optimizing the Post-CAR T Monitoring Period
Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director at Division of HMCT/University of Kansas Medical Center, shared a paper by Nausheen Ahmed et al on X:
“Out in press by Nausheen Ahmed and colleagues for ASH. Optimizing the Post-CAR T Monitoring Period for Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel.
- NRM beyond day 28 is largely driven by infection
- New-onset CRS and ICANS is rare after 2 weeks”
Source: Al-Ola A Abdallah/X
Authors: Nausheen Ahmed
William Wesson Forat Lutfi David L. Porter Veronika Bachanova Loretta J. Nastoupil Miguel-Angel Perales Richard T. Maziarz Jamie Brower Gunjan L Shah Andy I. Chen Olalekan O. Oluwole Stephen J. Schuster Michael R Bishop Joseph P. McGuirk Peter A. Riedell
Al-Ola A Abdallah
Andy I. Chen
ASH
cancer
David L. Porter
Forat Lutfi
Gunjan L. Shah
Jamie Brower
Joseph P. McGuirk
Loretta J. Nastoupil
Michael R Bishop
Miguel-Angel Perales
Nausheen Ahmed
Olalekan O. Oluwole
OncoDaily
Oncology
Peter A. Riedell
Plasma cell disorder
Post-CAR T
Richard T. Maziarz
Stephen J. Schuster
University of Kansas Medical Center
Veronika Bachanova
William Wesson